Essex Investment Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-220,160
| Closed | -$1.08M | – | 331 |
|
|
2024
Q1 | $1.08M | Buy |
220,160
+97,741
| +80% | +$579K | 0.21% | 142 |
|
|
2023
Q4 | $1.08M | Buy |
122,419
+38,671
| +46% | +$317K | 0.21% | 152 |
|
|
2023
Q3 | $961K | Sell |
83,748
-25,112
| -23% | -$483K | 0.16% | 207 |
|
|
2023
Q2 | $2.76M | Buy |
108,860
+247
| +0.2% | +$7.69K | 0.38% | 90 |
|
|
2023
Q1 | $3.5M | Buy |
108,613
+40,680
| +60% | +$1.27M | 0.51% | 57 |
|
|
2022
Q4 | $1.25M | Sell |
67,933
-689
| -1% | -$15.8K | 0.2% | 161 |
|
|
2022
Q3 | $1.85M | Buy |
68,622
+5,034
| +8% | +$102K | 0.3% | 103 |
|
|
2022
Q2 | $879K | Sell |
63,588
-921
| -1% | -$14.2K | 0.14% | 207 |
|
|
2022
Q1 | $1.26M | Sell |
64,509
-64,875
| -50% | -$984K | 0.16% | 197 |
|
|
2021
Q4 | $2.11M | Sell |
129,384
-1,941
| -1% | -$32.4K | 0.24% | 131 |
|
|
2021
Q3 | $3.66M | Hold |
131,325
| – | – | 0.45% | 61 |
|
|
2021
Q2 | $3.89M | Sell |
131,325
-7,664
| -6% | -$221K | 0.45% | 69 |
|
|
2021
Q1 | $3.88M | Buy |
138,989
+62,318
| +81% | +$1.72M | 0.47% | 58 |
|
|
2020
Q4 | $2.17M | Sell |
76,671
-23,329
| -23% | -$604K | 0.27% | 120 |
|
|
2020
Q3 | $2.51M | Buy |
100,000
+32,898
| +49% | +$863K | 0.36% | 75 |
|
|
2020
Q2 | $1.64M | Sell |
67,102
-32,898
| -33% | -$649K | 0.27% | 112 |
|
|
2020
Q1 | $1.48M | Buy |
+100,000
| New | +$2.07M | 0.3% | 103 |
|
|
2018
Q4 | – | Sell |
-87,355
| Closed | -$2.17M | – | 539 |
|
|
2018
Q3 | $2.17M | Hold |
87,355
| – | – | 0.26% | 121 |
|
|
2018
Q2 | $2.4M | Sell |
87,355
-24,005
| -22% | -$721K | 0.3% | 102 |
|
|
2018
Q1 | $3.43M | Sell |
111,360
-7,592
| -6% | -$244K | 0.45% | 59 |
|
|
2017
Q4 | $4.25M | Buy |
118,952
+14,024
| +13% | +$403K | 0.56% | 39 |
|
|
2017
Q3 | $2.89M | Sell |
104,928
-20,004
| -16% | -$485K | 0.39% | 64 |
|
|
2017
Q2 | $3.3M | Buy |
124,932
+26,248
| +27% | +$585K | 0.47% | 50 |
|
|
2017
Q1 | $2.05M | Buy |
98,684
+7,456
| +8% | +$153K | 0.32% | 85 |
|
|
2016
Q4 | $1.89M | Buy |
91,228
+5,228
| +6% | +$87.5K | 0.31% | 87 |
|
|
2016
Q3 | $1.39M | Buy |
86,000
+4,299
| +5% | +$62.4K | 0.22% | 109 |
|
|
2016
Q2 | $1.11M | Hold |
81,701
| – | – | 0.18% | 128 |
|
|
2016
Q1 | $1.43M | Buy |
81,701
+10,000
| +14% | +$204K | 0.24% | 90 |
|
|
2015
Q4 | $2.45M | Hold |
71,701
| – | – | 0.38% | 61 |
|
|
2015
Q3 | $2.13M | Hold |
71,701
| – | – | 0.35% | 64 |
|
|
2015
Q2 | $2.29M | Buy |
+71,701
| New | +$1.84M | 0.35% | 78 |
|
Other funds holding RVNC
PAI
PCH
SCM
RCMNY
Essex Investment Management's RVNC Position: Q2 2024 in Review
Essex Investment Management sold out of Revance Therapeutics, Inc. (RVNC) in Q2 2024, closing a stake of 220,160 shares — an estimated $1.08M sold.
Essex Investment Management first reported a position in RVNC in Q2 2015 and held it in 31 quarters. The position peaked at $4.25M in Q4 2017. 173 funds tracked by Wall St. Rank hold RVNC as of Q2 2024.
- Essex Investment Management reported no remaining Revance Therapeutics, Inc. position as of Q2 2024 after selling out during the quarter.
- Essex Investment Management sold 220,160 Revance Therapeutics, Inc. shares in Q2 2024, an estimated $1.08M.
- Essex Investment Management first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 31 quarters.
- Essex Investment Management's Revance Therapeutics, Inc. position peaked at $4.25M in Q4 2017.
- 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q2 2024.
Based on Essex Investment Management's 13F filing for Q2 2024, filed 12 Aug 2024.